September 09, 2021
aXichem Update – Entering the Commercial Phase september 2021
We create value.
aXichem is an innovative biotechnology company specialising in development of natural analogue ingredients.
We create value.
Aktiedata
AXICHEM A
(AXIC A)
20
SEK
-1.5 / -6.98%
High
20.1
Low
19.45
Volume
4927
Turnover
97821.5
January 27, 2022 11:01:38
Financial Calendar
Year-end report 2021 - 17 February 2022
Annual Report 2021 - 10 May 2022
Interim report 1/2022 - 24 May 2022
Annual general meeting 2022 - 31 May 2022
Interim report 2/2022 - 25 August 2022
Interim report 3/2021 - 24 November 2022
Year-end report 2022 - 23 February 2023
Company description
We draw from the genius of nature and respect nature in return.
aXichem Bolagsbeskrivning 131121
PDF 1.28 MB
Meetings Archive
Financial Advisor and Certified Advisor
Redeye AB
Box 7141
103 87 Stockholm
08-545 013 30
www.redeye.se
certifiedadviser@redeye.se
We create value.
Investor Structure
Largest owners as of 30 September 2021 aXichem’s ten largest owners according to the shareholders’ register kept by Euroclear
| Name | No. of shares | Participating interest (%) |
| Manakin Ltd | 1 842 055 | 11,14 |
| LMK -bolagen | 1 806 864 | 10,93 |
| Försäkringsaktiebolaget Avanza Pension | 1 144 836 | 6,92 |
| Nordnet Pensionsförsäkring AB | 675 147 | 4,08 |
| Pension Futur | 580 274 | 3,51 |
| Vasilis, Per | 353 047 | 2,14 |
| Kraft, Rolf | 331 782 | 2,01 |
| Redoterm AB | 318 947 | 1,93 |
| Fladvad, Per | 191 026 | 1,16 |
| Berger, Gunnar | 185 656 | 1,12 |
Investor enquiries
Subscribe to information
from Axichem via First
North.